ACSS2 and urinary bladder carcinoma: Studies have found that in patients receiving cisplatin chemotherapy and patients with complete remission of bladder cancer have lower levels of ACSS2, but patients with drug-resistant and progressive bladder cancer have higher levels of ACSS2 expression.